MADRIGAL PHARMACEUTICALS, INC. (MDGL) Current Ratio
- Current ratio · latest quarter: Value 3.20×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.20× | Current assets / current liabilities. $1.20B ÷ $374.20M ≈ 3.20× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.20B USD | Assets, Current |
| Current obligations | 374.20M USD | Liabilities, Current |
| Cash and equivalents | 292.73M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 546.03M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 192.31M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 99.39M USD | Inventory, Net |
| Payables | 34.51M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.20B | $374.20M | $292.73M | $546.03M | $192.31M | $99.39M | $34.51M | (m) | 3.20× |
| 2026-03-31 | $1.18B | $338.26M | $227.03M | $585.74M | $187.36M | $112.07M | $60.80M | (m) | 3.50× |
| 2025-12-31 | $1.25B | $310.29M | $198.69M | $784.87M | $134.48M | $74.84M | $48.88M | (m) | 4.01× |
| 2025-09-30 | $1.35B | $391.41M | $295.69M | $814.05M | $113.28M | $69.32M | $44.94M | (m) | 3.44× |
| 2025-06-30 | $1.00B | $196.50M | $186.19M | $610.83M | $79.23M | $63.50M | $37.98M | (m) | 5.11× |
| 2025-03-31 | $987.98M | $167.24M | $183.65M | $659.42M | $61.43M | $55.24M | $42.06M | (m) | 5.91× |
| 2024-12-31 | $1.03B | $169.28M | $100.02M | $826.23M | $53.82M | $34.07M | $43.60M | (m) | 6.10× |
| 2024-09-30 | $1.06B | $177.85M | $232.68M | $765.94M | $30.46M | $8.71M | $45.97M | (m) | 5.98× |
| 2024-06-30 | $1.09B | $125.16M | $494.60M | $563.20M | $6.90M | $7.07M | $8.99M | (m) | 8.72× |
| 2024-03-31 | $1.07B | $114.34M | $622.52M | $436.55M | (m) | $854.00K | $21.53M | (m) | 9.39× |
| 2023-12-31 | $637.28M | $118.55M | $99.92M | $534.22M | $0.00 | $0.00 | $28.04M | (m) | 5.38× |
| 2023-09-30 | $235.47M | $99.67M | $62.05M | $170.30M | (m) | (m) | $16.54M | (m) | 2.36× |
| 2023-06-30 | $301.60M | $99.71M | $77.20M | $221.22M | (m) | (m) | $17.53M | (m) | 3.02× |
| 2023-03-31 | $331.28M | $98.35M | $113.31M | $216.17M | (m) | (m) | $12.13M | (m) | 3.37× |
| 2022-12-31 | $361.37M | $115.89M | $331.55M | $27.23M | (m) | (m) | $23.83M | (m) | 3.12× |
| 2022-09-30 | $157.11M | $98.92M | $59.34M | $93.85M | (m) | (m) | $18.56M | (m) | 1.59× |
| 2022-06-30 | $214.55M | $84.01M | $53.27M | $158.49M | (m) | (m) | $11.29M | (m) | 2.55× |
| 2022-03-31 | $221.17M | $76.64M | $42.28M | $177.67M | (m) | (m) | $22.78M | (m) | 2.89× |
| 2021-12-31 | $271.68M | $76.84M | $36.27M | $234.08M | (m) | (m) | $21.38M | (m) | 3.54× |
| 2021-09-30 | $302.96M | $69.33M | $49.17M | $249.97M | (m) | (m) | $10.42M | (m) | 4.37× |
| 2021-06-30 | $326.07M | $56.71M | $33.54M | $290.31M | (m) | (m) | $1.07M | (m) | 5.75× |
| 2021-03-31 | $308.05M | $48.79M | $44.20M | $263.02M | (m) | (m) | $4.40M | (m) | 6.31× |
| 2020-12-31 | $285.16M | $46.56M | $54.00M | $230.15M | (m) | (m) | $1.02M | (m) | 6.13× |
| 2020-09-30 | $337.60M | $49.37M | $109.12M | $226.82M | (m) | (m) | $6.28M | (m) | 6.84× |
| 2020-06-30 | $386.60M | $45.27M | $61.87M | $322.51M | (m) | (m) | $5.00M | (m) | 8.54× |
| 2020-03-31 | $409.49M | $25.70M | $66.65M | $341.86M | (m) | (m) | $1.11M | (m) | 15.93× |
| 2019-12-31 | $440.20M | $25.13M | $46.70M | $392.35M | (m) | (m) | $1.18M | (m) | 17.52× |
| 2019-09-30 | $455.32M | $15.46M | $89.49M | $364.12M | (m) | (m) | $773.00K | (m) | 29.44× |
| 2019-06-30 | $468.79M | $12.32M | $72.51M | $393.89M | (m) | (m) | $446.00K | (m) | 38.06× |
| 2019-03-31 | $478.39M | $10.46M | $47.49M | $430.33M | (m) | (m) | $4.38M | (m) | 45.75× |
| 2018-12-31 | $485.20M | $8.44M | $57.38M | $426.34M | (m) | (m) | $2.49M | (m) | 57.46× |
| 2018-09-30 | $489.31M | $6.64M | $38.05M | $450.49M | (m) | (m) | $1.03M | (m) | 73.67× |
| 2018-06-30 | $491.27M | $5.44M | $264.86M | $225.44M | (m) | (m) | $588.00K | (m) | 90.37× |
| 2018-03-31 | $183.20M | $6.29M | $38.13M | $144.70M | (m) | (m) | $1.42M | (m) | 29.11× |
| 2017-12-31 | $192.01M | $10.05M | $148.63M | $42.90M | (m) | (m) | $1.93M | (m) | 19.10× |
| 2017-09-30 | $62.72M | $8.52M | $12.96M | $49.18M | (m) | (m) | $1.40M | (m) | 7.36× |
| 2017-06-30 | $67.95M | $6.44M | $34.80M | $32.37M | (m) | (m) | $1.28M | (m) | 10.56× |
| 2017-03-31 | $40.35M | $5.91M | $8.21M | $31.91M | (m) | (m) | $2.78M | (m) | 6.83× |
| 2016-12-31 | $41.21M | $4.80M | $19.14M | $21.36M | (m) | (m) | $762.00K | (m) | 8.58× |
| 2016-09-30 | $41.19M | $3.92M | $8.39M | $31.16M | (m) | (m) | $1.16M | (m) | 10.52× |
| 2016-06-30 | $44.84M | $3.36M | $10.76M | $32.26M | (m) | (m) | $680.00K | (m) | 13.33× |
| 2016-03-31 | $52.60M | $8.64M | $42.81M | $9.23M | (m) | (m) | $744.00K | (m) | 6.09× |
| 2015-12-31 | $363.58K | $49.28M | $306.25K | (m) | (m) | (m) | $102.29K | (m) | 0.01× |
| 2015-09-30 | $90.23M | $30.63M | $45.54M | $42.72M | (m) | (m) | $1.42M | (m) | 2.95× |
| 2015-06-30 | $100.55M | $32.52M | $32.00M | $66.33M | (m) | (m) | $3.02M | (m) | 3.09× |
| 2015-03-31 | $77.97M | $30.92M | $33.26M | $43.35M | (m) | (m) | $3.74M | (m) | 2.52× |
| 2014-12-31 | $99.35M | $30.89M | $46.02M | $51.67M | (m) | (m) | $3.14M | (m) | 3.22× |
| 2014-09-30 | $122.19M | $32.96M | $68.48M | $50.80M | (m) | (m) | $4.44M | (m) | 3.71× |
| 2014-06-30 | $114.32M | $32.67M | $96.81M | $15.25M | (m) | (m) | $5.23M | (m) | 3.50× |
| 2014-03-31 | $80.39M | $32.37M | $52.03M | $26.75M | (m) | (m) | $5.81M | (m) | 2.48× |
| 2013-12-31 | $92.24M | $32.21M | $48.49M | $42.99M | (m) | (m) | $6.59M | (m) | 2.86× |
| 2013-09-30 | $54.74M | $25.93M | $25.48M | $27.91M | (m) | (m) | $5.69M | (m) | 2.11× |
| 2013-06-30 | $71.84M | $20.07M | $33.78M | $36.42M | (m) | (m) | $5.22M | (m) | 3.58× |
| 2013-03-31 | $91.87M | $16.55M | $34.96M | $55.43M | (m) | (m) | $5.72M | (m) | 5.55× |
| 2012-12-31 | $101.39M | $23.49M | $81.51M | $19.09M | (m) | (m) | $5.66M | (m) | 4.32× |
| 2012-09-30 | $55.94M | $18.96M | $29.44M | $25.70M | (m) | (m) | $3.69M | (m) | 2.95× |
| 2012-06-30 | $45.49M | $18.25M | $25.59M | $19.06M | (m) | (m) | $3.47M | (m) | 2.49× |
| 2012-03-31 | $58.00M | $15.64M | $34.55M | $22.84M | (m) | (m) | $3.04M | (m) | 3.71× |
| 2011-12-31 | $40.29M | $15.15M | $30.07M | $9.65M | (m) | (m) | $3.47M | (m) | 2.66× |
| 2011-09-30 | $52.02M | $17.12M | $20.64M | $30.02M | (m) | (m) | $2.92M | (m) | 3.04× |
| 2011-06-30 | $63.72M | $15.35M | $25.89M | $37.00M | (m) | (m) | $2.00M | (m) | 4.15× |
| 2010-12-31 | $51.52M | $16.74M | $31.31M | $19.66M | (m) | (m) | $1.93M | (m) | 3.08× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |